RxDoctor Payments Data

Thomas Barnard, MD

Ophthalmology · Lake Mary, FLNPI 1487654117

Payments from drug & device makers

$7,426in general payments, 2019–2025

Across 212 payments — averaging $35.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • US Retina LLC$3K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Alimera Sciences, Inc.$836
  • Genentech USA, Inc.$731
  • Apellis Pharmaceuticals, Inc.$508
  • AbbVie$468
  • plus $1K from 9 others

What the payments were for

  • Food & beverage$4,53661%
  • Education$981%
  • Ownership interest$1,13015%
  • Other$1,66322%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,426 in reported general payments places this provider in the 75th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$5,965,422
Medicare patients
1,613
Services billed
33,729

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EyleaAflibercept109$271,584
VabysmoFaricimab-Svoa29$83,877
SyfovrePegcetacoplan/Pf18$65,700
RestasisCyclosporine15$13,391
Prednisolone Acetate339$12,163
LumiganBimatoprost15$4,326
Latanoprost270$3,061
Loteprednol Etabonate23$2,936
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha142$1,811
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat122$1,632
Timolol Maleate137$1,573
Brimonidine Tartrate170$1,208
Brinzolamide11$1,130
Atropine Sulfate23$781
ValacyclovirValacyclovir Hcl13$723

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Regeneron Healthcare Solutions, Inc.Eylea$1,022$271,584109 claims
Genentech USA, Inc.Vabysmo$731$83,87729 claims
Apellis Pharmaceuticals, Inc.Syfovre$508$65,70018 claims
AbbVieRestasis, Lumigan$468$17,71730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Lake Mary

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →